PT  - JOURNAL ARTICLE
AU  - Jean-sebastien Casalegno
AU  - Etienne Javouhey
AU  - Dominique Ploin
AU  - Martine Valette
AU  - Remi Fanget
AU  - Sandrine Couray Targe
AU  - Anne-Florence Myar-Dury
AU  - Muriel Doret-Dion
AU  - Mona Massoud
AU  - Phillipe Vanhems
AU  - Olivier Claris
AU  - Marine Butin
AU  - Florence Ader
AU  - Sylvie Bin
AU  - Alexandre Gaymard
AU  - Bruno Lina
AU  - Florence Morfin
AU  - VRS study group in Lyon
AU  - Yves Gillet
TI  - Delayed Start of the Respiratory Syncytial Virus Epidemic at the End of the 20/21 Northern Hemisphere Winter Season, Lyon, France
AID  - 10.1101/2021.03.12.21253446
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.12.21253446
4099  - http://medrxiv.org/content/early/2021/03/12/2021.03.12.21253446.short
4100  - http://medrxiv.org/content/early/2021/03/12/2021.03.12.21253446.full
AB  - The implementation of Non Pharmaceutical Interventions (NPI), triggered by the emergence of covid-19, decrease the RSV circulation. Data, from our ongoing surveillance; show a late introduction of RSV at the end of December and a 4 month delayed epidemic start without significant change in our NPI policy. This data indicates that RSV still have the potential to give a late season outbreak in northern hemisphere. RSV surveillance should be reinforced and RSV Pharmaceutical Interventions maintained for at risk neonateCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Surveillance data from laboratory database. There was no access to individual clinical record. Data are aggregate and do no present individual result.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpdate Surveillance data are available on request